Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles

Authors Kim JH, Chung HH, Jeong MS, Song MR, Kang KW, Kim JS

Received 11 March 2013

Accepted for publication 28 April 2013

Published 21 June 2013 Volume 2013:8(1) Pages 2247—2257

DOI https://doi.org/10.2147/IJN.S45059

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Jin Hyun Kim,1,* Hyun Hoon Chung,2,* Min Sook Jeong,1 Mi Ryoung Song,1 Keon Wook Kang,3,4 Jun Sung Kim1

1R&D Center, Biterials Co, Ltd, Seoul, Republic of Korea; 2Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea; 3Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; 4Cancer Research Institute, Seoul National University, Seoul, Republic of Korea

*These authors contributed equally to this work

Abstract: Ovarian cancer is the fifth-leading cause of cancer-related deaths among women as a result of late diagnosis. For survival rates to improve, more sensitive and specific methods for earlier detection of ovarian cancer are needed. This study presents the development of rapid and specific one-step circulating tumor cell (CTC) detection using flow cytometry in a whole-blood sample with fluorescent silica nanoparticles. We prepared magnetic nanoparticle (MNP)-SiO2(rhodamine B isothiocyanate [RITC]) (MNP-SiO2[RITC] incorporating organic dyes [RITC, λmax(ex/em) = 543/580 nm]) in the silica shell. We then controlled the amount of organic dye in the silica shell of MNP-SiO2(RITC) for increased fluorescence intensity to overcome the autofluorescence of whole blood and increase the sensitivity of CTC detection in whole blood. Next, we modified the surface function group of MNP-SiO2(RITC) from –OH to polyethylene glycol (PEG)/COOH and conjugated a mucin 1 cell surface-associated (MUC1) antibody on the surface of MNP-SiO2(RITC) for CTC detection. To study the specific targeting efficiency of MUC1-MNP-SiO2(RITC), we used immunocytochemistry with a MUC1-positive human ovarian cancer cell line and a negative human embryonic kidney cell line. This technology was capable of detecting 100 ovarian cancer cells in 50 µL of whole blood. In conclusion, we developed a one-step CTC detection technology in ovarian cancer based on multifunctional silica nanoparticles and the use of flow cytometry.

Keywords: circulating tumor cells, CTCs, fluorescent nanoprobe, MUC1, ovarian cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]